We are studying a new CAR T-cell therapy for individuals with refractory generalized myasthenia gravis. The goal is to evaluate its safety and effectiveness in improving muscle strength.
Health conditions and diseases that the clinical trial is designed to study and treat.
Myasthenia gravis (MG) is a chronic autoimmune disorder that leads to weakness in the skeletal muscles, which are responsible for movement. This condition can cause fluctuating muscle weakness, particularly in the eyes, face, and throat.
Refractory generalized myasthenia gravis is a severe form of MG that does not respond adequately to standard treatments, leading to persistent muscle weakness and significant challenges in daily functioning.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.